Scottish Medicines Consortium recommends three drugs but rejects Remicade
This article was originally published in Scrip
Executive Summary
Scotland's health technology appraisal body, the Scottish Medicines Consortium (SMC), has given the nod for three drugs to be made available via NHS Scotland. But Merck & Co was unable to persuade the consortium that its ulcerative colitis drug Remicade (infliximab) was value for money.